S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.51
+1.83
+10.97%
OSRH · OSR Health, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$0.12
-0.13
(-53.17%)
● At close: August 25 at 4:00:00 PM EDT
DAY'S RANGE
$0.12
$0.09
$0.25
52-WEEK RANGE
$0.12
$0.07
$0.91
What's happening
- OSRH is down 53.17% today, trading at $0.12. — Live quote
- Volume today (120,968) is well below its 3-month average of 7,058,120. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.16 actual vs. $-0.10 estimated (-56.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 4
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (7 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OSRH
-62.79%
vs S&P 500
-75.57%
1-YEAR RETURN
OSRH
-70.97%
vs S&P 500
-85.53%
6-MONTH RETURN
OSRH
-61.91%
3-MONTH RETURN
OSRH
-52.02%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-01-26 (Q4 2025)
$-0.16
Est. $-0.10
MISS -56.9%
2025-10-26 (Q3 2025)
$-0.10
Est. $-0.12
BEAT +18.3%
Valuation Measures & Ratios
Enterprise Value4$11.3M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)4.08
Price / Book70.11
EV4 / Revenue6.25
EV4 / EBITDA—
Profit Margin-593.22%
Operating Margin-933.74%
Return on Equity (ROE8)-11.67%
Return on Assets (ROA9)-6.24%
Avg Volume (3M)7,058,120
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short960,109
Change from Prior Settlement-3.21%
% of Float—
Days to Cover (Short Ratio)1.69
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -72.2% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -593.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -71.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OSRH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $315.7K | $484.1K | $627.7K | $1.1M | $761.3K | $823.0K | — | — |
| Gross profit | $86.6K | $160.3K | $261.7K | $32.8K | $168.7K | $179.1K | $232.3K | $239.8K |
| Operating income | -$3.0M | -$3.7M | -$3.8M | -$5.2M | -$2.9M | -$3.6M | -$3.2M | -$3.3M |
| Net income | — | — | — | — | — | -$231.0K | -$97.3K | -$60.4K |
| EPS (diluted) | — | $-0.08 | — | — | $-1.04 | $-0.06 | $-0.02 | $-0.01 |
| EPS (basic) | $-0.02 | $-0.09 | $-0.10 | $0.02 | $-1.04 | $-1.56 | $-0.41 | $-0.60 |
| Operating margin | -$961 | -$758 | -$606 | -$461 | -$383 | -$433 | — | — |
| Net margin | — | — | — | — | — | -$28 | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $166.6M | $172.2M | $171.2M | $177.3M | $185.4M | $174.6M | $175.2M | $20.9M |
| Total liabilities | $41.7M | $44.8M | $44.2M | $43.1M | $46.3M | $42.3M | $32.0M | $6.0M |
| Stockholders' equity | — | — | — | — | — | — | -$8.3M | -$5.8M |
| Total current assets | $2.9M | $2.9M | $2.8M | $3.2M | $2.9M | $3.5M | $2.3M | $39.6K |
| Total current liabilities | $15.7M | $17.9M | $17.2M | $15.0M | $15.9M | $13.9M | $3.5M | $3.9M |
| Cash & equivalents | $1.5M | $1.6M | $1.7M | $2.2M | $1.6M | $1.6M | $341.5K | $12.2K |
| Accounts receivable | $188.8K | $261.4K | $319.3K | $489.2K | $742.8K | $794.5K | $904.5K | — |
| Inventory | $594.3K | $462.5K | $196.4K | $185.1K | $198.8K | $736.6K | $922.1K | — |
| Other current assets | $371.8K | $312.4K | $263.5K | $250.8K | $281.7K | $280.4K | $74.6K | — |
| Property, plant & equipment | $142.3K | $153.5K | $169.1K | $98.1K | $3.7K | $999 | $2.3K | — |
| Goodwill | $29.2M | $29.7M | $24.9M | $25.5M | $26.4M | $24.4M | $24.4M | $26.6M |
| Intangible assets | $134.1M | $139.0M | $142.5M | $148.2M | $155.6M | $146.2M | $148.1M | — |
| Accrued liabilities | $1.1M | $1.1M | $957.9K | $977.4K | $906.6K | $726.3K | $459.9K | — |
| Short-term debt | $2.1M | $2.2M | $2.3M | $1.9M | $1.8M | $1.6M | $1.8M | — |
| Other current liabilities | $966.7K | $978.2K | $971.4K | $963.3K | $2.1M | $1.0M | $79.8K | $87.0K |
| Long-term debt | $271.3K | $272.9K | — | $0 | — | $253.0K | $497.6K | — |
| Other non-current liabilities | $66.6K | $66.5K | $1.7K | $1.7K | $1.8K | $1.7K | $1.7K | — |
| Common stock & paid-in capital | $3.5K | $3.3K | $2.7K | $2.4K | $2.0K | $1.9K | $216 | $216 |
| Retained earnings | -$41.0M | -$40.1M | -$37.2M | -$32.3M | -$30.2M | -$30.6M | -$19.2M | -$5.8M |
| Accumulated other comprehensive income (loss) | -$2.1M | -$1.7M | $3.8M | $4.7M | $7.0M | $241.7K | -$225.4K | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.4M | -$1.0M | -$1.1M | -$2.7M | -$482.6K | -$64.1K | -$181.0K | -$686.5K |
| Investing cash flow | -$88.3K | $11.7K | -$2.6M | -$726.6K | -$528.4K | $1.2M | -$187.8K | $245.2K |
| Financing cash flow | $2.5M | $942.1K | $3.2M | $4.1M | $891.5K | $149.4K | $321.5K | $338.0K |
| Free cash flow | — | — | — | — | -$485.3K | — | — | — |
| Capital expenditures | — | — | — | — | $2.7K | — | — | — |
| Deferred income taxes | — | — | — | — | — | — | $739.9K | — |
| Change in inventory | $144.9K | $65.5K | $20.9K | -$11.8K | -$583.3K | -$189.5K | -$33.7K | $146.7K |
| Purchases of investments | — | — | — | — | — | — | $480.0K | — |
| Share repurchases | — | — | — | — | — | — | $19.2M | $0 |
| Debt issued | — | — | — | — | — | — | -$1.9K | -$592 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $2.9M | $3.5M | — | — | — |
| Gross profit | $592.9K | $811.2K | — | — | — |
| Operating income | -$18.3M | -$11.7M | -$1.8M | -$35.4K | -$3.3K |
| Net income | — | -$2.4M | $403.8K | -$35.4K | -$3.3K |
| EPS (diluted) | $-0.80 | $-4.79 | $0.05 | $-0.01 | — |
| EPS (basic) | $-0.92 | $-4.79 | $0.05 | $-0.01 | — |
| Operating margin | -$631 | -$331 | — | — | — |
| Net margin | — | -$68 | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $171.2M | $175.2M | $36.6M | $1.2M | $705.1K |
| Total liabilities | $44.2M | $32.0M | $4.1M | $1.3M | $707.2K |
| Stockholders' equity | — | -$8.3M | -$3.9M | -$37.5K | -$2.1K |
| Total current assets | $2.8M | $2.3M | $22.6K | $124.5K | $4.8K |
| Total current liabilities | $17.2M | $3.5M | $2.0M | $1.3M | $707.2K |
| Cash & equivalents | $1.7M | $341.5K | $15.4K | $124.5K | $4.8K |
| Accounts receivable | $319.3K | $904.5K | — | — | — |
| Inventory | $196.4K | $922.1K | — | — | — |
| Other current assets | $263.5K | $74.6K | — | — | — |
| Property, plant & equipment | $169.1K | $2.3K | — | — | — |
| Goodwill | $24.9M | $24.4M | $27.8M | — | — |
| Intangible assets | $142.5M | $148.1M | — | — | — |
| Accrued liabilities | $957.9K | $459.9K | — | — | — |
| Short-term debt | $2.3M | $1.8M | — | — | — |
| Other current liabilities | $971.4K | $79.8K | $72.0K | $17.0K | — |
| Long-term debt | — | $497.6K | — | — | — |
| Other non-current liabilities | $1.7K | $1.7K | — | — | — |
| Common stock & paid-in capital | $2.7K | $216 | $216 | $173 | $173 |
| Retained earnings | -$37.2M | -$19.2M | -$3.9M | -$62.5K | -$27.1K |
| Accumulated other comprehensive income (loss) | $3.8M | -$225.4K | — | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.3M | -$1.8M | -$818.8K | -$4.2K | -$461 |
| Investing cash flow | -$2.6M | $503.6K | -$33.8M | — | — |
| Financing cash flow | $8.4M | $1.2M | $34.5M | $124.0K | -$57.4K |
| Deferred income taxes | — | $739.9K | $342.4K | — | — |
| Change in inventory | -$763.7K | -$305.6K | — | — | — |
| Purchases of investments | — | $480.0K | $180.0K | — | — |
| Share repurchases | — | $36.2M | $36.0M | — | — |
| Debt issued | — | $236.7K | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OSRH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 14 most recent filings · covers 2023-02-14 to 2025-02-14
Recent transactions
- Most recent: Bellevue Global Life Science Investors LLC (10% owner) — Other acquisition/disposition of 43,000 shares on 2025-02-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Bellevue Global Life Science Investors LLC | 10% owner | Other acquisition/disposition | 2025-02-14 | 43,000 |
| Hwang Kuk Hyoun | President and CEO | Other acquisition/disposition | 2025-02-14 | 43,000 |
| Yoo David Jin | Chief Financial Officer | Grant / award | 2023-03-23 | 20,000 |
| REED STEVEN | Director | Grant / award | 2023-02-14 | 20,000 |
| Chung In Chul | Director | Grant / award | 2023-02-14 | 20,000 |
| Roberts Rad | Director | Grant / award | 2023-02-14 | 20,000 |
| Park Jin Whan | Director | Grant / award | 2023-02-14 | 20,000 |
| Euh Hosun | Director | Grant / award | 2023-02-14 | 20,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-02-14 | Bellevue Global Life Science Investors LLC | 10% owner | Other acquisition/disposition | 43,000 | $0.00 |
| 2025-02-14 | Hwang Kuk Hyoun | President and CEO | Other acquisition/disposition | 43,000 | $0.00 |
| 2025-02-14 | Hwang Kuk Hyoun | President and CEO | Other acquisition/disposition | 7,531,634 | $0.00 |
| 2025-02-14 | Hwang Kuk Hyoun | President and CEO | Other acquisition/disposition | 3,123,970 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-02 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-08-28 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-25 | 8-K | 2026-08-25 | View on SEC.gov → |
| 2026-08-19 | 8-K | 2026-08-19 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-31 | View on SEC.gov → |
| 2026-06-17 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-05 | View on SEC.gov → |
| 2026-06-02 | 8-K | 2026-05-27 | View on SEC.gov → |
Recent news
Headlines about OSRH (OSR Health, Inc.). Links open the publisher — we don’t host full articles.
-
OSRH 8-K & SEC Filings
Yahoo Finance · 2026-10-17 -
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
Yahoo Finance · 2026-08-27 -
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
Yahoo Finance · 2026-08-21 -
OSR Health faces Nasdaq delisting over bid-price rule
Seeking Alpha · 2026-08-19 -
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
Yahoo Finance · 2026-08-19 -
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
Yahoo Finance · 2026-08-19 -
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
Yahoo Finance · 2026-08-11 -
OSR Health, Inc. (OSRH) Shareholder/Analyst Call Prepared Remarks Transcript
Seeking Alpha · 2026-08-07
No headlines in this category right now — try “All”.